1. Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics 
Vincent T. Ma, Philip S. Boonstra, Kamal Menghrajani, Cecelia Perkins, Krisstina L. Gowin, Ruben A. Mesa, Jason R. Gotlib, Moshe Talpaz 
Clinical Lymphoma, Myeloma and Leukemia 
Volume 18, Issue 5, Pages e201-e210 (May 2018)
DOI: /j.clml
Copyright © 2018 The Authors Terms and Conditions

2. Figure 1
Kaplan-Meier Analysis of Median Time to Death From Diagnosis Stratified by Baseline Cytogenetics Status
Clinical Lymphoma, Myeloma and Leukemia  , e201-e210DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

3. Figure 2
Kaplan-Meier Analysis of Median Time to Death From Diagnosis for Patients Who Received Only Best Available Therapy Stratified by Baseline Cytogenetics Status
Clinical Lymphoma, Myeloma and Leukemia  , e201-e210DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

4. Figure 3
Visualization of Fitted Model for Predicted Survival for BAT and JAK Inhibitor Therapy
Abbreviations: BAT = best available therapy; JAK = Janus kinase.
Clinical Lymphoma, Myeloma and Leukemia  , e201-e210DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

5. Supplemental Figure 1
Kaplan-Meier Analysis of Median Time to Death From Initiation of JAK Inhibitor (JAKi) Therapy Stratified by Baseline Cytogenetics Status
Abbreviation: JAK = Janus kinase.
Clinical Lymphoma, Myeloma and Leukemia  , e201-e210DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions

6. Supplemental Figure 2
Kaplan-Meier Analysis of Transformation-Free Survival Stratified by Baseline Cytogenetics Status
Clinical Lymphoma, Myeloma and Leukemia  , e201-e210DOI: ( /j.clml )
Copyright © 2018 The Authors Terms and Conditions